Omicron infection enhances Delta antibody immunity in vaccinated persons.

Ad26COVS1 / immunology Antibodies, Neutralizing / immunology Antibodies, Viral / immunology BNT162 Vaccine / immunology COVID-19 / immunology COVID-19 Vaccines / immunology Cross Protection / immunology Humans SARS-CoV-2 / classification Vaccination / statistics & numerical data

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
07 2022
Historique:
received: 27 01 2022
accepted: 04 05 2022
pubmed: 7 5 2022
medline: 16 7 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

The extent to which Omicron infection

Identifiants

DOI: 10.1038/s41586-022-04830-x PMID: 35523247 PMC: PMC9279144
pubmed: 35523247
doi: 10.1038/s41586-022-04830-x
pii: 10.1038/s41586-022-04830-x
pmc: PMC9279144
doi:

Substances chimiques

Ad26COVS1 JT2NS6183B
Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-359

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI138546
Pays : United States
Organisme : Wellcome Trust
ID : 221003/Z/20/Z
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Investigateurs

Rohen Harrichandparsad (R)
Kobus Herbst (K)
Prakash Jeena (P)
Thandeka Khoza (T)
Henrik Kløverpris (H)
Alasdair Leslie (A)
Rajhmun Madansein (R)
Mohlopheni Marakalala (M)
Mosa Moshabela (M)
Kogie Naidoo (K)
Zaza Ndhlovu (Z)
Thumbi Ndung'u (T)
Kennedy Nyamande (K)
Vinod Patel (V)
Theresa Smit (T)
Adrie Steyn (A)
Emily Wong (E)

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2022. The Author(s).

Références

Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature https://doi.org/10.1038/s41586-021-04387-1 (2021).
Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022).
doi: 10.1056/NEJMoa2119451
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
doi: 10.1038/s41586-021-04385-3
Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484 (2022).
doi: 10.1016/j.cell.2021.12.046
Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022).
doi: 10.1016/S0140-6736(21)02844-0
Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466 (2022).
doi: 10.1016/j.cell.2021.12.033
Lu, L. et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab1041 (2021).
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
doi: 10.1038/s41586-021-04389-z
VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490–495 (2022).
doi: 10.1038/s41591-021-01678-y
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature https://doi.org/10.1038/d41586-021-03832-5 (2021).
Davies, M.-A. et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop. Med. Int. Health https://doi.org/10.1111/tmi.13752 (2022).
Wolter, N. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 399, 437–446 (2022).
doi: 10.1016/S0140-6736(22)00017-4
Sigal, A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat. Rev. Immunol. 22, 69–71 (2022).
doi: 10.1038/s41577-022-00678-4
Lyngse, F. P. et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households. Preprint at medRxiv https://doi.org/10.1101/2022.01.28.22270044 (2022).
Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154–162 (2022).
doi: 10.1016/j.chom.2022.01.005
Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).
doi: 10.1056/NEJMoa2114228
Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142–146 (2021).
doi: 10.1038/s41586-021-03471-w
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
Rössler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386, 698–700 (2022).
doi: 10.1056/NEJMc2119236
Servellita, V. et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 185, 1539–1548 (2022).
doi: 10.1016/j.cell.2022.03.019
Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N. Engl. J. Med. 386, 1579–1580 (2022).
Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe https://doi.org/10.1016/j.chom.2022.03.029 (2022).
Chemaitelly, H. et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Preprint at medRxiv https://doi.org/10.1101/2022.02.24.22271440 (2022).
Stegger, M. et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. Preprint at medRxiv https://doi.org/10.1101/2022.02.19.22271112 (2022).
Khan, K. et al. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab1008 (2021).
Madhi, S. A. et al. Population immunity and Covid-19 severity with Omicron Variant in South Africa. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119658 (2022).
Sigal, A., Milo, R. & Jassat, W. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat. Rev. Immunol. 22, 267–269 (2022).
doi: 10.1038/s41577-022-00720-5
Smith, M. et al. Age, disease severity and ethnicity influence humoral responses in a multi-ethnic COVID-19 cohort. Viruses 13, 786 (2021).
doi: 10.3390/v13050786

Auteurs

Khadija Khan (K)

Africa Health Research Institute, Durban, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
ORCID: 0000-0001-7565-7400

Farina Karim (F)

Africa Health Research Institute, Durban, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

Sandile Cele (S)

Africa Health Research Institute, Durban, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.

Kajal Reedoy (K)

Africa Health Research Institute, Durban, South Africa.

James Emmanuel San (JE)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
ORCID: 0000-0002-5736-664X

Gila Lustig (G)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.

Houriiyah Tegally (H)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.

Yuval Rosenberg (Y)

Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.
ORCID: 0000-0002-6681-8329

Mallory Bernstein (M)

Africa Health Research Institute, Durban, South Africa.

Zesuliwe Jule (Z)

Africa Health Research Institute, Durban, South Africa.

Yashica Ganga (Y)

Africa Health Research Institute, Durban, South Africa.

Nokuthula Ngcobo (N)

Africa Health Research Institute, Durban, South Africa.

Matilda Mazibuko (M)

Africa Health Research Institute, Durban, South Africa.

Ntombifuthi Mthabela (N)

Africa Health Research Institute, Durban, South Africa.

Zoey Mhlane (Z)

Africa Health Research Institute, Durban, South Africa.

Nikiwe Mbatha (N)

Africa Health Research Institute, Durban, South Africa.

Yoliswa Miya (Y)

Africa Health Research Institute, Durban, South Africa.

Jennifer Giandhari (J)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.

Yajna Ramphal (Y)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.

Taryn Naidoo (T)

Africa Health Research Institute, Durban, South Africa.

Aida Sivro (A)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.

Natasha Samsunder (N)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.

Ayesha B M Kharsany (ABM)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.

Daniel Amoako (D)

National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Jinal N Bhiman (JN)

National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Nithendra Manickchund (N)

Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.

Quarraisha Abdool Karim (Q)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Nombulelo Magula (N)

Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa.

Salim S Abdool Karim (SS)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Glenda Gray (G)

South African Medical Research Council, Cape Town, South Africa.

Willem Hanekom (W)

Africa Health Research Institute, Durban, South Africa.
Division of Infection and Immunity, University College London, London, UK.

Anne von Gottberg (A)

National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
ORCID: 0000-0002-0243-7455

Ron Milo (R)

Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.
ORCID: 0000-0003-1641-2299

Bernadett I Gosnell (BI)

Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
ORCID: 0000-0002-6336-7489

Richard J Lessells (RJ)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
ORCID: 0000-0003-0926-710X

Penny L Moore (PL)

Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
ORCID: 0000-0001-8719-4028

Tulio de Oliveira (T)

KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
Department of Global Health, University of Washington, Seattle, WA, USA.

Mahomed-Yunus S Moosa (MS)

Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
ORCID: 0000-0001-6191-4023

Alex Sigal (A)

Africa Health Research Institute, Durban, South Africa. alex.sigal@ahri.org.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. alex.sigal@ahri.org.
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. alex.sigal@ahri.org.
Max Planck Institute for Infection Biology, Berlin, Germany. alex.sigal@ahri.org.
ORCID: 0000-0001-8571-2004

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Ad26COVS1 › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Protection croisée › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Omicron infection enhances Delta antibody...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Omicron infection enhances Delta antibody...